Methylprednisolone for acute spinal cord injury：a Meta-analysis of therapeutic efficacy and adverse reactions
10.3969/j.issn.2095-4344.2015.42.026
- VernacularTitle:甲基强的松龙修复急性脊髓损伤：效果与不良反应的Meta分析
- Author:
Wentao ZHAO
;
Hongbing YUAN
;
Panpan LI
;
Haifeng ZHANG
;
Mingqing LIU
- Publication Type:Journal Article
- From:
Chinese Journal of Tissue Engineering Research
2015;(42):6868-6874
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Methylprednisolone has been used for the treatment of acute spinal cord injury but there is a dispute about the efficacy and safety of methylprednisolon. OBJECTIVE:To evaluate the efficacy and safety of methylprednisolon based on system review. METHODS:PubMed database, EMBASE database, Cochrane Library, ISI Web of knowledge, CBM database, VIP database, CNKI database and Wanfang database were searched from their start year up to December 2014 for relevant randomized clinical trials on the treatment of acute spinal cord injury with methylprednisolon. RESULTS AND CONCLUSION:Twelve randomized clinical trials with 642 acute spinal cord injury patients were included. The results of the Meta analysis showed: methylprednisolone+conventional therapy was better to improve American Spinal Injury Association (ASIA) motor function score, ASIA touch sensation score, ASIA pinprick sensation score and the overal Frankel score than the conventional therapy alone (control group) with statistical significance (P < 0.05). In the aspect of safety, the methylprednisolone group had higher death ratio, digestive tract reaction ratio and urinary infection ratio than the control group but with no statistical significance. The gastrointestinal bleeding ratio and lung infection ratio was significantly higher in the methylprednisolone group than the control group (P < 0.05). We conclude that methylprednisolone has protective effect on acute spinal cord injury, but the main side effects are gastrointestinal bleeding and lung infection. There is a need for high-quality randomized controled trials to prove the efficiency and safety of methylprednisolone.
